Bessemer Group
TNGX icon

Bessemer Group’s Tango Therapeutics TNGX Stock Holding History

Bessemer Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Sell
354,206
-354,192
-50% -$8.76M 0.02% 378
2026
Q1 		$14.8M Hold
708,398
– – 0.02% 308
2025
Q4 		$6.28M Hold
708,398
– – 0.01% 376
2025
Q3 		$5.95M Buy
708,398
+14
+0% +$95 0.01% 345
2025
Q2 		$3.63M Hold
708,384
– – 0.01% 395
2025
Q1 		$970K Hold
708,384
– – ﹤0.01% 710
2024
Q4 		$2.19M Hold
708,384
– – ﹤0.01% 630
2024
Q3 		$5.46M Hold
708,384
– – 0.01% 403
2024
Q2 		$6.08M Hold
708,384
– – 0.01% 347
2024
Q1 		$5.63M Hold
708,384
– – 0.01% 371
2023
Q4 		$7.01M Hold
708,384
– – 0.01% 338
2023
Q3 		$7.98M Hold
708,384
– – 0.02% 292
2023
Q2 		$2.35M Hold
708,384
– – 0.01% 461
2023
Q1 		$2.8M Hold
708,384
– – 0.01% 410
2022
Q4 		$5.14M Hold
708,384
– – 0.01% 328
2022
Q3 		$2.56M Hold
708,384
– – 0.01% 406
2022
Q2 		$3.21M Buy
+708,384
New +$4.29M 0.01% 367

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bessemer Group's TNGX Position: Q2 2026 in Review

Bessemer Group reduced its Tango Therapeutics (TNGX) stake by 50% in Q2 2026, selling an estimated $8.76M and leaving 354,206 shares worth $11.1M. The position accounts for 0.02% of the portfolio, ranked #378.

Bessemer Group first reported a position in TNGX in Q2 2022 and has held it in 17 quarters since. The position peaked at $14.8M in Q1 2026. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Bessemer Group held 354,206 shares of Tango Therapeutics worth $11.1M as of Q2 2026.
  • Bessemer Group sold 354,192 Tango Therapeutics shares in Q2 2026, an estimated $8.76M.
  • Tango Therapeutics made up 0.02% of Bessemer Group's portfolio in Q2 2026, its #378 holding.
  • Bessemer Group first reported a position in Tango Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Bessemer Group's Tango Therapeutics position peaked at $14.8M in Q1 2026.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.